Palladium-109 labeled anti-melanoma monoclonal antibodies
Patent
·
OSTI ID:875259
- Setauket, NY
- Pelham, NY
- Scarsdale, NY
Palladium-109, a beta-emitting radionuclide, when chelated to anti-melanoma monoclonal antibody demonstrates high uptake in melanoma and thus is useful for tumor therapy.
- Research Organization:
- Brookhaven National Laboratory (BNL), Upton, NY (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC02-76CH00016
- Assignee:
- United States of America as represented by Secretary of Energy (Washington, DC)
- Patent Number(s):
- H000819
- Application Number:
- 06/605439
- OSTI ID:
- 875259
- Country of Publication:
- United States
- Language:
- English
Similar Records
Palladium-109 labeled anti-melanoma monoclonal antibodies
Palladium-109 labeled anti-melanoma monoclonal antibodies
Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy
Patent
·
Tue Sep 04 00:00:00 EDT 1990
·
OSTI ID:1176622
Palladium-109 labeled anti-melanoma monoclonal antibodies
Patent
·
Mon Apr 30 00:00:00 EDT 1984
·
OSTI ID:6110979
Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy
Journal Article
·
Sun Jul 01 00:00:00 EDT 1984
· J. Nucl. Med.; (United States)
·
OSTI ID:6668913
Related Subjects
/424/435/436/530/
anti-melanoma
anti-melanoma monoclonal
antibodies
antibody
beta-emitting
chelated
demonstrates
emitting radionuclide
labeled
melanoma
monoclonal
monoclonal antibodies
monoclonal antibody
palladium-109
radionuclide
statutory invention registration
therapy
tumor
tumor therapy
uptake
useful
anti-melanoma
anti-melanoma monoclonal
antibodies
antibody
beta-emitting
chelated
demonstrates
emitting radionuclide
labeled
melanoma
monoclonal
monoclonal antibodies
monoclonal antibody
palladium-109
radionuclide
statutory invention registration
therapy
tumor
tumor therapy
uptake
useful